Spondylarthritis

You have full text access to this OnlineOpen article

The early disease stage in axial spondylarthritis: Results from the german spondyloarthritis inception cohort†

  1. Martin Rudwaleit1,‡,
  2. Hildrun Haibel1,§,
  3. Xenofon Baraliakos2,
  4. Joachim Listing3,
  5. Elisabeth Märker-Hermann4,¶,
  6. Henning Zeidler5,
  7. Jürgen Braun2,
  8. Joachim Sieper1,‖,*

Article first published online: 26 FEB 2009

DOI: 10.1002/art.24483

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 60, Issue 3, pages 717–727, March 2009

Additional Information

How to Cite

Rudwaleit, M., Haibel, H., Baraliakos, X., Listing, J., Märker-Hermann, E., Zeidler, H., Braun, J. and Sieper, J. (2009), The early disease stage in axial spondylarthritis: Results from the german spondyloarthritis inception cohort. Arthritis & Rheumatism, 60: 717–727. doi: 10.1002/art.24483

Author Information

  1. 1

    Charité Medical University Hospital, Campus Benjamin Franklin, and German Rheumatism Research Centre, Berlin, Germany

  2. 2

    Centre of Rheumatology Herne, Herne, and Ruhr-University Bochum, Bochum, Germany

  3. 3

    German Rheumatism Research Centre, Berlin, Germany

  4. 4

    Dr. Horst-Schmidt Hospital, Wiesbaden, Germany

  5. 5

    Hannover Medical School, Hannover, Germany

  1. ‡

    Dr. Rudwaleit has received consulting fees from Abbott, Centocor, Schering-Plough, and Wyeth (less than $10,000 each), and speaking fees from Abbott, Centocor, Schering-Plough, Pfizer, Wyeth, and Merck, Sharp, and Dohme (less than $10,000 each).

  2. §

    Dr. Haibel has received consulting fees, speaking fees, and/or honoraria from Abbott and Schering-Plough (less than $10,000 each).

  3. Dr. Märker-Hermann has received speaking fees from Wyeth, Abbott Immunology, and Essex (less than $10,000 each).

  4. ‖

    Dr. Sieper has received speaking fees and/or honoraria from Abbott, Schering-Plough, Wyeth, Pfizer, and Roche (less than $10,000 each).

*Charité Medical University Hospital, Campus Benjamin Franklin, Rheumatology, Medical Department I, Hindenburgdamm 30, 12203 Berlin, Germany

  1. †

    The German Spondyloarthritis Inception Cohort is supported by the German Ministry for Education and Research (BMBF) (grant FKZ 01G19946), as part of the German Competence Network in Rheumatology. Amgen, Centocor, Schering-Plough, and Wyeth have provided support equally since 2005, when BMBF funding was reduced as scheduled. Abbott Immunology has provided an equal part of the support since 2006.

Publication History

  1. Issue published online: 26 FEB 2009
  2. Article first published online: 26 FEB 2009
  3. Manuscript Accepted: 7 NOV 2008
  4. Manuscript Received: 14 APR 2008

Funded by

  • German Ministry for Education and Research (BMBF). Grant Number: FKZ 01G19946

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (134K)

REFERENCES

  • 1
    Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369: 1379–90.
  • 2
    Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002; 61(Suppl 3): iii8–18.
  • 3
    Amor B, Dougados M, Mijiyawa M. [ Criteria of the classification of spondylarthropathies.] Rev Rhum Mal Osteoartic 1990; 57: 85–9. In French.
  • 4
    Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al, for the European Spondylarthropathy Study Group. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218–27.
    Direct Link:
  • 5
    Zink A, Braun J, Listing J, Wollenhaupt J, and the German Collaborative Arthritis Centers. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis: results from the German rheumatological database. J Rheumatol 2000; 27: 613–22.
  • 6
    Boonen A, van der Heijde D, Landewe R, Guillemin F, Rutten-van Molken M, Dougados M, et al. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 2003; 62: 732–40.
  • 7
    Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A, and the German Collaborative Arthritis Centres. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006; 65: 1175–83.
  • 8
    Mau W, Listing J, Huscher D, Zeidler H, Zink A. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 2005; 32: 721–8.
  • 9
    Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361–8.
  • 10
    Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003; 23: 61–6.
  • 11
    Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004; 63: 535–43.
  • 12
    Bollow M, Braun J, Hamm B, Eggens U, Schilling A, Konig H, et al. Early sacroiliitis in patients with spondyloarthropathy: evaluation with dynamic gadolinium-enhanced MR imaging. Radiology 1995; 194: 529–36.
  • 13
    Oostveen J, Prevo R, den Boer J, van de Laar M. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography: a prospective, longitudinal study. J Rheumatol 1999; 26: 1953–8.
  • 14
    Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005; 52: 1000–8.
    Direct Link:
  • 15
    Uhrin Z, Kuzis S, Ward MM. Exercise and changes in health status in patients with ankylosing spondylitis. Arch Intern Med 2000; 160: 2969–75.
  • 16
    Brophy S, Pavy S, Lewis P, Taylor G, Bradbury L, Robertson D, et al. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J Rheumatol 2001; 28: 2667–73.
  • 17
    Heuft-Dorenbosch L, van Tubergen A, Spoorenberg A, Landewe R, Dougados M, Mielants H, et al. The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. Arthritis Rheum 2004; 51: 154–9.
    Direct Link:
  • 18
    Vander Cruyssen B, Ribbens C, Boonen A, Mielants H, de Vlam K, Lenaerts J, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007; 66: 1072–7.
  • 19
    Collantes E, Zarco P, Munoz E, Juanola X, Mulero J, Fernandez-Sueiro JL, et al. Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. Rheumatology (Oxford) 2007; 46: 1309–15.
  • 20
    Lee W, Reveille JD, Davis JC Jr, Learch TJ, Ward MM, Weisman MH. Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis 2007; 66: 633–8.
  • 21
    Dougados M. Diagnostic features of ankylosing spondylitis. Br J Rheumatol 1995; 34: 301–5.
  • 22
    Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. JAMA 1977; 237: 2613–4.
  • 23
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286–91.
  • 24
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281–5.
  • 25
    Ware JE, Kosinski M, Keller SD. A 12-item Short Form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220–33.
  • 26
    Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994; 21: 1694–8.
  • 27
    Creemers MC, Franssen MJ, van 't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005; 64: 127–9.
  • 28
    Wanders AJ, Landewe RB, Spoorenberg A, Dougados M, van der Linden S, Mielants H, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum 2004; 50: 2622–32.
    Direct Link:
  • 29
    Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006; 54: 569–78.
    Direct Link:
  • 30
    Sampaio-Barros PD, Bertolo MB, Kraemer MH, Marques-Neto JF, Samara AM. Undifferentiated spondyloarthropathies: a 2-year follow-up study. Clin Rheumatol 2001; 20: 201–6.
  • 31
    Resnick D, Dwosh IL, Goergen TG, Shapiro RF, Utsinger PD, Wiesner KB, et al. Clinical and radiographic abnormalities in ankylosing spondylitis: a comparison of men and women. Radiology 1976; 119: 293–7.
  • 32
    Gran JT, Husby G, Hordvik M, Stormer J, Romberg-Andersen O. Radiological changes in men and women with ankylosing spondylitis. Ann Rheum Dis 1984; 43: 570–5.
  • 33
    Boyer GS, Templin DW, Bowler A, Lawrence RC, Heyse SP, Everett DF, et al. Spondyloarthropathy in the community: differences in severity and disease expression in Alaskan Eskimo men and women. J Rheumatol 2000; 27: 170–6.
  • 34
    Boyer GS, Templin DW, Cornoni-Huntley JC, Everett DF, Lawrence RC, Heyse SF, et al. Prevalence of spondyloarthropathies in Alaskan Eskimos. J Rheumatol 1994; 21: 2292–7.
  • 35
    Brandt J, Bollow M, Haberle J, Rudwaleit M, Eggens U, Distler A, et al. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology (Oxford) 1999; 38: 831–6.
  • 36
    Chou CT, Lin KC, Wei JC, Tsai WC, Ho HH, Hwang CM, et al. Study of undifferentiated spondyloarthropathy among first-degree relatives of ankylosing spondylitis probands. Rheumatology (Oxford) 2005; 44: 662–5.
  • 37
    Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 2006; 65: 1147–53.
  • 38
    Huerta-Sil G, Casasola-Vargas JC, Londono JD, Rivas-Ruiz R, Chavez J, Pacheco-Tena C, et al. Low grade radiographic sacroiliitis as prognostic factor in patients with undifferentiated spondyloarthritis fulfilling diagnostic criteria for ankylosing spondylitis throughout follow up. Ann Rheum Dis 2006; 65: 642–6.
  • 39
    Amor B, Santos RS, Nahal R, Listrat V, Dougados M. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 1994; 21: 1883–7.
  • 40
    Linssen A, Feltkamp TE. B27 positive diseases versus B27 negative diseases. Ann Rheum Dis 1988; 47: 431–9.
  • 41
    Saraux A, de Saint-Pierre V, Baron D, Valls I, Koreichi D, Youinou P, et al. The HLA B27 antigen-spondylarthropathy association: impact on clinical expression. Rev Rhum Engl Ed 1995; 62: 487–91.
  • 42
    Jaakkola E, Herzberg I, Laiho K, Barnardo MC, Pointon JJ, Kauppi M, et al. Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. Ann Rheum Dis 2006; 65: 775–80.
  • 43
    Wanders A, Landewe R, Dougados M, Mielants H, van der Linden S, van der Heijde D. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 2005; 64: 988–94.
  • 44
    Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of adalimumab in the treatment of axial spondyloarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008; 58: 1981–91.
    Direct Link:
  • 45
    Barnham N, Keen H, Coates L, O'Connor P, Hensor E, Fraser A, et al. A randomised controlled trial of infliximab shows clinical and MRI efficacy in patients with HLA B27 positive very early ankylosing spondylitis [abstract]. Arthritis Rheum 2007; 56: 4237.
  • 46
    Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D, for the ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 316–20.
  • 47
    Boers M. Predicting outcome of ankylosing spondylitis: prognosis or hindsight? J Rheumatol 1994; 21: 1789–90.
  • 48
    Dincer U, Cakar E, Kiralp MZ, Dursun H. Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol 2008; 27: 457–62.
  • 49
    Brandt HC, Spiller I, Song IH, Vahldiek JL, Rudwaleit M, Sieper J. Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis 2007; 66: 1479–84.
  • 50
    Zink A, Thiele K, Huscher D, Listing J, Sieper J, Krause A, et al, for the German Collaborative Arthritis Centres. Healthcare and burden of disease in psoriatic arthritis: a comparison with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006; 33: 86–90.
View Full Article (HTML) Get PDF (134K)